The Effect of Surgically Induced Weight Loss on Endocrine Function, Cardiovascular Function and Body Composition
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00686972 |
Recruitment Status
:
Terminated
(PI left JHU)
First Posted
: May 30, 2008
Results First Posted
: July 2, 2017
Last Update Posted
: July 2, 2017
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Bariatric Surgery | Drug: GLP-1 | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 51 participants |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Other |
Official Title: | The Effect of Surgically Induced Weight Loss on Endocrine Function, Cardiovascular Function and Body Composition |
Actual Study Start Date : | May 2007 |
Actual Primary Completion Date : | October 2010 |
Actual Study Completion Date : | October 2010 |

Arm | Intervention/treatment |
---|---|
Experimental: GLP-1
5 ng/kg/min, IV for 1 hour during each clamp study (7) over 2 year period.
|
Drug: GLP-1
5 ng/kg/min, IV for 1 hour during each clamp study (7) over 2 year period.
Other Name: Glucagon-like Peptide-1
|
- Insulin Secretion [ Time Frame: 2 years ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 21 Years to 65 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Male and female volunteers 21-65 years.
- BMI > 40.
- Preoperative hematocrit level of at least 34% for women and 38% for men.
- Postoperative hematocrit level of at least 34% for women and 36% for men.
Exclusion Criteria:
- Volunteers whose hematocrit level does not meet the above criteria.
- Pregnant and or lactating females.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00686972
United States, Maryland | |
Johns Hopkins Bayview Medical Center | |
Baltimore, Maryland, United States, 21224 |
Principal Investigator: | Dariush Elahi, PhD | Johns Hopkins University |
Responsible Party: | Johns Hopkins University |
ClinicalTrials.gov Identifier: | NCT00686972 History of Changes |
Other Study ID Numbers: |
NA_00004876 |
First Posted: | May 30, 2008 Key Record Dates |
Results First Posted: | July 2, 2017 |
Last Update Posted: | July 2, 2017 |
Last Verified: | June 2017 |
Keywords provided by Johns Hopkins University:
Bariatric Surgery Glucose Regulation Cardiac Function Body Composition |
Additional relevant MeSH terms:
Weight Loss Body Weight Changes Body Weight Signs and Symptoms Glucagon-Like Peptide 1 Glucagon |
Incretins Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Gastrointestinal Agents |